DD

Business profile & competitive position

DuPont de Nemours, Inc. is classified in the Basic Materials sector, specifically the Chemicals industry. That places it in the business of producing specialty chemicals, advanced materials, and industrial biosciences used by customers ranging from electronics and healthcare to transportation and construction. The industry is typically capital-intensive and cyclical, requiring scale, R&D investment, and long customer qualification cycles.

What the current profitability numbers actually say is more muted. DuPont’s net margin is 0.7% and its return on equity is 0.3%. Those are extremely low figures. In a sector where durable competitive advantages usually show up as steady margins and healthy returns on capital, a 0.7% net margin and 0.3% ROE suggest the company is not currently converting sales or equity into meaningful bottom-line profit. That does not mean there is no competitive position—DuPont has historically held technology and patent strength—but right now the headline returns are weak. The numbers alone do not support a strong-moat narrative; instead, they indicate that earnings have been depressed, possibly by legacy litigation charges, restructuring, or low pricing power relative to costs.

Financial posture

DuPont’s market capitalization stands at $19.2 billion, and the stock closed at $142.18 with the latest snapshot. The trailing P/E ratio is 309.1. A P/E north of 300 is unusually high for a chemicals company and implies the market is pricing in a substantial earnings recovery rather than paying for current profitability. With a net margin of 0.7% and ROE of 0.3%, the valuation is clearly disconnected from the recent income statement.

The beta is 1.09, which means DuPont carries slightly above-average market sensitivity, broadly in line with a cyclical industrial name. On August 5, GuruFocus published a piece titled “Is DuPont de Nemours Inc (DD) Overvalued After 3.1% Rally? GF Value Says Overvalued,” suggesting that by at least one valuation model the rally had pushed the shares past fair value. That same day, Zacks reported that DuPont’s Q2 earnings call pointed to faster second-half growth. So the investment debate is straightforward: reported earnings are tiny, the multiple is huge, and much of the case rests on whether management’s second-half acceleration materializes.

Macro & geopolitical exposure

As a Chemicals company in Basic Materials, DuPont is exposed to several macro and geopolitical forces. Feedstock and energy costs—especially natural gas, oil derivatives, and petrochemical inputs—directly affect profitability. The industry is also sensitive to industrial production, construction activity, and semiconductor capital spending, since chemicals are used throughout the manufacturing chain.

Trade policy matters too. Tariffs, import quotas, and cross-border logistics constraints can raise input costs or limit market access. Currency fluctuations affect reported results because chemical sales are global. On the regulatory side, environmental rules are a first-order risk. The August 7 Reuters headline—New Jersey’s $2.5 billion “forever chemicals” settlements with DuPont, 3M, and others winning court approval—illustrates the kind of PFAS-related litigation and cleanup liability that is an ongoing industry-wide issue. Healthcare innovation, highlighted by the August 6 R&D 100 Award, shows a growth avenue, but it does not remove the legacy exposure tied to chemical production and environmental regulation.

Recent developments

Four items have shaped the recent narrative. On August 7, 2026, Reuters reported that New Jersey’s $2.5 billion “forever chemicals” settlements with DuPont, 3M, and others won court approval. That resolves a specific piece of litigation, but it also confirms that large environmental settlements remain part of the chemical-industry landscape and a line item that can move company financials.

On August 6, 2026, PRNewswire announced that DuPont won an R&D 100 Award for innovation in healthcare. That supports the company’s effort to reposition toward higher-value, less commoditized applications, even if the revenue contribution is not broken out in the headline.

On August 5, 2026, GuruFocus asked whether the stock was overvalued after a 3.1% rally and concluded its GF Value model flagged the name as overvalued. Also on August 5, 2026, Zacks summarized DuPont’s Q2 earnings call as pointing to faster second-half growth. Read together, the recent news captures the tension: valuation concerns are colliding with management optimism about an operational pickup in the back half of 2026.

Earnings behavior & post-earnings drift

DuPont’s earnings history over the last eight reported quarters is striking: the company has beaten estimates 8 out of 8 times, for a 100% beat rate, with an average earnings surprise of 53.5%. The average five-day price move after earnings across those quarters is +3.41%, classified as an upward post-earnings drift.

The four most recent quarters show how this has played out. On August 4, 2026, DuPont reported EPS of $1.88 against the $1.76 estimate, a 6.8% beat; the stock rose 3.11% the next day but delivered a 0% five-day move. On May 5, 2026, actual EPS was $1.65 versus an estimate of $0.4881, a 238% surprise; the stock added 1.69% the next session and 2.64% over the following five days. On February 10, 2026, EPS of $0.46 beat the $0.43 estimate by 7%; the next-day move was 4.25% and the five-day drift was 3.88%. On November 6, 2025, EPS of $1.09 trounced the $0.4656 estimate by 134.1%; the stock moved 1.66% the next day and 3.7% over the next five days.

The next scheduled report is November 5, 2026, before the market opens, with a consensus EPS estimate of $1.88. With the stock at $142.18, the 50-day EMA at $140.16, and RSI at 54.4, DuPont is neither technically overbought nor oversold heading into that report. The historical pattern suggests the market has rewarded beats, but the magnitude of the 238% and 134.1% surprises in the past year also shows that comparisons can be volatile. Past drift was positive on average, yet the most recent quarter saw the five-day follow-through collapse to 0%, a reminder that post-earnings momentum is not guaranteed.

For a deeper understanding of DuPont’s positioning, it is worth reviewing the full institutional verdict, including analyst consensus estimates, rating distributions, and detailed valuation models, before forming an opinion.